Symbols

KYMR

Kymera Therapeutics·NASDAQ

--(--)

Market Open: --

--(--)

Pre-Market: --

Signals Analysis

Bullish signal 3

Bearish signal 2

Consensus Rating "Strong Buy"

Ample Liquidity

High Gross Profit Margin

EPS Below Expectations

Revenue Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About KYMR

Kymera Therapeutics, Inc.

A clinical-stage biopharmaceutical company that delivering novel small molecule protein degrader medicines used to degrade disease-causing proteins

Industry

Biological Technology

Established Date

05/25/2017

Listing Date

08/21/2020

Exchange

NASDAQ Stock Exchange

Full-time Employees

188

Fiscal Year Ends

12-31

Website

www.kymeratx.com

Security Type

Common stock

Office address

200 Arsenal Yards Blvd., Suite 230, Watertown, Massachusetts 02472

Business

Introduction

Kymera Therapeutics, Inc., a limited liability company incorporated on May 25, 2017 under the laws of the State of Delaware. The company is a biopharmaceutical company dedicated to the discovery and development of novel small molecule therapies that selectively degrade disease-causing proteins by utilizing drugs.

Earnings Call

Q1/2025

Estimate EPS-0.91

Actual EPS-0.82

Estimate Revenue10.73M

Actual Revenue22.10M

Contradictions Unveiled: IRF5 Degradation, TYK2 Strategy Shift, and Th2 Biomarker Expectations in Q1 2025

May 20,2025 02:40·
Earnings Decrypt

Q2/2025

Estimate EPS-0.8

Actual EPS-0.95

Estimate Revenue24.16M

Actual Revenue11.48M

Kymera Therapeutics Q2 2025: Unpacking Contradictions in Clinical Expectations, Safety Monitoring, and Dosing Strategies

Aug 11,2025 01:37·
Earnings Decrypt

Company Financials

EPS

KYMR has released its 2025 Q3 earnings. EPS was reported at -0.94, versus the expected -0.79, missing expectations. The chart below visualizes how KYMR has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

KYMR has released its 2025 Q3 earnings report, with revenue of 2.76M, reflecting a YoY change of -26.12%, and net profit of -82.17M, showing a YoY change of -31.51%. The Sankey diagram below clearly presents KYMR's revenue sources and cost distribution.